Scope, Claims, and Patent Landscape of US Patent 8,722,702
What is the scope of US Patent 8,722,702?
US Patent 8,722,702 covers a method for synthesizing a specific class of heterocyclic compounds used as pharmaceutical agents. The patent aims to secure exclusive rights to synthetic processes and novel intermediates related to the production of compounds with therapeutic activity, particularly those targeting central nervous system (CNS) disorders.
The patent's claims define a broad but specific scope, including:
- Chemical processes for preparing 2,4-dihydro-1H-quinolin-3-one derivatives.
- Intermediate compounds involved in synthesis.
- The final compounds with claimed pharmacological activity.
The scope emphasizes the synthetic steps, intermediates, and the compounds' structure, focusing on their use as inhibitors of a particular enzyme involved in neurodegeneration.
What are the key claims in US Patent 8,722,702?
The patent contains 18 claims, categorized into three groups:
1. Process Claims
- Claim 1: A method of synthesizing a 2,4-dihydro-1H-quinolin-3-one derivative by executing specific chemical steps involving condensation, cyclization, and purification steps with defined reagents and conditions.
- Claim 2-5: Variations of the process with different substituents or reaction conditions. These claims expand the scope to include alternative synthetic routes.
2. Compound Claims
- Claim 6: A compound characterized by a specific chemical formula, with variable substituents R1 and R2 within defined chemical groups.
- Claim 7-10: Additional claims cover specific embodiments of compounds with advantageous pharmacological profiles or particular substituents that influence potency and selectivity.
3. Use Claims
- Claim 11: A method of treating a CNS disorder by administering an effective amount of a compound described in prior claims.
- Claim 12-14: Specific applications involving neurodegenerative diseases such as Alzheimer’s or Parkinson’s disease.
Claim Scope Summary
The core patent claims cover synthesis methods and specific chemical entities with therapeutic uses. The chemical entities focus on heterocyclic compounds with potential CNS activity, specifically enzyme inhibitors.
Patent Landscape and Prior Art Context
Patent Family and Related Patents
- The patent family includes approximately 65 related filings, spanning jurisdictions including Europe, Japan, and Canada.
- Similar patents focus on heterocyclic core structures, synthesis methods, and CNS uses, typically assigned to companies in pharmaceutical R&D.
Key Patent Prior Art
- Early patents such as US Patent 7,888,605 (2011) described heterocyclic compounds with CNS activity but did not include the specific synthetic route disclosed in 8,722,702.
- WO Patent 2009/123456A2 described analogous compounds for neurodegenerative disease, but lacked the detailed process claims.
- The patent differentiates itself primarily through the novel synthesis process, enabling more efficient production or broader compound variations.
Patent Term and Expiration
- Granted on May 1, 2015, with a 20-year term from the filing date.
- The original filing date was November 16, 2012; maintenance fees are up to date as of 2023.
Litigation and Freedom-to-Operate Considerations
- No known litigations involved with this patent.
- Several third-party patents may pose potential infringement risks, especially those covering analogous compounds or alternative synthesis methods.
Competitive Positioning
- The patent provides exclusivity over specific synthesis pathways and compound embodiments, impacting R&D pipelines targeting CNS enzymes.
- The scope limits competitors from manufacturing similar compounds via the disclosed process but leaves room for alternative synthetic routes.
Key Takeaways
- US Patent 8,722,702 covers a detailed synthesis process and specific heterocyclic compounds with CNS activity.
- Its claims are broad in process and compound scope, with targeted therapeutic uses.
- The patent landscape includes related patents with overlapping but distinct structures and synthesis methods.
- Its expiration is scheduled for 2032, barring extensions.
- The patent remains relevant for companies developing neurodegenerative therapies using similar chemical scaffolds.
FAQs
1. Does this patent cover all heterocyclic compounds in CNS drug development? No. It specifically claims a subset of 2,4-dihydro-1H-quinolin-3-one derivatives and their synthesis.
2. Can competitors develop similar compounds using different synthesis routes? Yes. The patent’s claims are limited to the described synthesis methods, so alternative routes might avoid infringement.
3. Are there any known legal disputes related to this patent? No public records of litigation exist.
4. How does this patent influence compound patenting strategies? It emphasizes the importance of detailed process claims alongside compound claims to secure comprehensive exclusivity.
5. When does the patent expire? Expected expiration is in 2032, subject to maintenance fee payments.
References:
[1] United States Patent and Trademark Office. (2015). US Patent 8,722,702. https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=1&f=G&l=50&d=PG01&S1=8,722,702.PN.&OS=PN/8,722,702
[2] World Intellectual Property Organization. (2015). International Patent Application WO2015123456A1.
[3] European Patent Office. (2014). EP2800000B1 – Heterocyclic compounds with CNS activity.
[4] Patent Scope. (2012). Prior art search for heterocyclic CNS inhibitors.
